270 related articles for article (PubMed ID: 30271152)
21. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders.
Boyer L; Falissard B; Nuss P; Collin C; Duret S; Rabbani M; De Chefdebien I; Tonelli I; Llorca PM; Fond G
Mol Psychiatry; 2023 Sep; 28(9):3709-3716. PubMed ID: 37479781
[TBL] [Abstract][Full Text] [Related]
22. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
23. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.
Ostuzzi G; Bertolini F; Tedeschi F; Vita G; Brambilla P; Del Fabro L; Gastaldon C; Papola D; Purgato M; Nosari G; Del Giovane C; Correll CU; Barbui C
World Psychiatry; 2022 Jun; 21(2):295-307. PubMed ID: 35524620
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia.
Huang CY; Fang SC; Shao YJ
JAMA Netw Open; 2021 May; 4(5):e218810. PubMed ID: 33974056
[TBL] [Abstract][Full Text] [Related]
25. Time to rehospitalization in patients with bipolar mania discharged on long-acting injectable or oral antipsychotics.
Lin CH; Chan HY; Hsu CC; Chen FC
J Affect Disord; 2021 Jan; 279():292-298. PubMed ID: 33096327
[TBL] [Abstract][Full Text] [Related]
26. Extent of use of long-acting injectable antipsychotics in children and adolescents within Indiana Medicaid.
Modesitt T; Kubascik E; Ott C
Ment Health Clin; 2018 Sep; 8(5):202-207. PubMed ID: 30206502
[TBL] [Abstract][Full Text] [Related]
27. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
28. Long-Acting Injectables Versus Oral Antipsychotics: A Retrospective Bidirectional Mirror-Image Study.
Miura G; Misawa F; Kawade Y; Fujii Y; Mimura M; Kishimoto T
J Clin Psychopharmacol; 2019; 39(5):441-445. PubMed ID: 31415288
[TBL] [Abstract][Full Text] [Related]
29. Effects of four atypical antipsychotics on autonomic nervous system activity in schizophrenia.
Hattori S; Kishida I; Suda A; Miyauchi M; Shiraishi Y; Fujibayashi M; Tsujita N; Ishii C; Ishii N; Moritani T; Taguri M; Hirayasu Y
Schizophr Res; 2018 Mar; 193():134-138. PubMed ID: 28709776
[TBL] [Abstract][Full Text] [Related]
30. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
31. Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in Japan.
Onitsuka T; Okada T; Hasegawa N; Tsuboi T; Iga JI; Yasui-Furukori N; Yamada N; Hori H; Muraoka H; Ohi K; Ogasawara K; Ochi S; Takeshima M; Ichihashi K; Fukumoto K; Iida H; Yamada H; Furihata R; Makinodan M; Takaesu Y; Numata S; Komatsu H; Hishimoto A; Kido M; Atake K; Yamagata H; Kikuchi S; Hashimoto N; Usami M; Katsumoto E; Asami T; Kubota C; Matsumoto J; Miura K; Hirano Y; Watanabe K; Inada K; Hashimoto R
J Clin Psychopharmacol; 2023 Jul-Aug 01; 43(4):365-368. PubMed ID: 37216369
[TBL] [Abstract][Full Text] [Related]
32. Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations.
Liu Y; Patterson ME; Sahil S; Stoner SC
Front Pharmacol; 2023; 14():1140969. PubMed ID: 37284307
[No Abstract] [Full Text] [Related]
33. Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia.
Fang SC; Huang CY; Shao YJ
J Clin Psychiatry; 2022 Jun; 83(4):. PubMed ID: 35649156
[No Abstract] [Full Text] [Related]
34. Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study.
Magliocco F; de Filippis R; Aloi M; Staltari FA; Gaetano R; Segura-Garcia C; De Fazio P
Int J Psychiatry Clin Pract; 2020 Jun; 24(2):201-207. PubMed ID: 32134336
[No Abstract] [Full Text] [Related]
35. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.
Gentile S
Pharmacotherapy; 2013 Oct; 33(10):1087-106. PubMed ID: 23776129
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
37. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J
Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of Neuroleptic Malignant Syndrome With Depot Versus Oral Antipsychotics: A Systematic Review and Pooled, Patient-Level Analysis of 662 Case Reports.
Guinart D; Misawa F; Rubio JM; Pereira J; Sharma H; Schoretsanitis G; Kane JM; Correll CU
J Clin Psychiatry; 2020 Nov; 82(1):. PubMed ID: 33238083
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis.
Lian L; Kim DD; Procyshyn RM; Fredrikson DH; Cázares D; Honer WG; Barr AM
Early Interv Psychiatry; 2022 Jun; 16(6):589-599. PubMed ID: 34263540
[TBL] [Abstract][Full Text] [Related]
40. Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.
Lian L; Kim DD; Procyshyn RM; Cázares D; Honer WG; Barr AM
PLoS One; 2022; 17(4):e0267808. PubMed ID: 35486616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
